Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi

Apr 22 2017

• By Scrip Team

Related Content

Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck

Jul 22 2016

BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim

Dec 02 2016

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Feb 17 2017

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth

Feb 01 2017

Cancer Programs Critical For 'New AstraZeneca' As Price Pressure, Regulatory Changes Loom In 2017

Feb 03 2017

Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

Feb 03 2017

Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business

Mar 02 2017

Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?

Mar 21 2017

Novartis Pursues Disease-Modifying Differentiator For Cosentyx In Psoriasis

Mar 22 2017

Mylan’s Generic Advair Delay Gives Leverage To Rivals

Mar 29 2017

Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

Mar 29 2017

Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

Mar 23 2017

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

Oct 04 2016

AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

Jan 18 2017

Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Jan 25 2017

Biogen Forecasts Gradual Launch For Life-Transforming Drug Spinraza

Jan 26 2017

Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

Apr 20 2017

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

Apr 20 2017

Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales

Apr 18 2017

Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo

Apr 04 2017

Promise Of US Tax Reform Simmers, But On The Backburner

Apr 12 2017

AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind

Apr 12 2017

Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal

Apr 13 2017

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Apr 14 2017

ALEX Ups The Ante For Alecensa In ALK+ NSCLC

Apr 10 2017

IDO Emerges As Clean Combo Partner, Rising Star At AACR

Apr 05 2017

Related Companies

Johnson & Johnson

Biogen, Inc.

Bristol Myers Squibb Company

Novartis AG

Eli Lilly and Company

Incyte Corporation

Johnson & Johnson

Amgen, Inc.

GSK plc

Bristol Myers Squibb Company

Incyte Corporation

AstraZeneca PLC

Johnson & Johnson

Johnson & Johnson

AbbVie Inc.

Eli Lilly and Company

Roche Holding AG

Bristol Myers Squibb Company

Merck & Co., Inc.

Pfizer Inc.

Sanofi

Boehringer Ingelheim GmbH

Additional Topics

Sales & Earnings Companies Business Strategies Strategy Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window